Influence of DHA-Rich Supplement on DHA-Status and Health Evolution of Patients With Cystic Fibrosis

This study is ongoing, but not recruiting participants.

First Received: September 12, 2005 Last Updated: December 19, 2007 History of Changes

Sponsors and Collaborators:	University Hospital, Ghent Belgian Society against Cystic Fibrosis
Information provided by:	University Hospital, Ghent
ClinicalTrials.gov Identifier:	NCT00221546

Purpose

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

Condition	Intervention	Phase
Cystic Fibrosis	Drug: Giving DHA-rich supplement versus placebo	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title:	Influence of DHA-Rich Supplement on DHA-Status and Health Evolution of Patients With Cystic Fibrosis

Resource links provided by NLM:

Genetics Home Reference related topics: cystic fibrosis

MedlinePlus related topics: Cystic Fibrosis Dietary Supplements

Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:

Clinical evolution: weight, height, pulmonary function and infection frequency before the study start and during the 2 years of the study

Secondary Outcome Measures:

Estimated Enrollment:	30
Study Start Date:	September 2004
Estimated Study Completion Date:	April 2007

Detailed Description:

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00221546

Locations

Sponsors and Collaborators

University Hospital, Ghent

Belgian Society against Cystic Fibrosis

Investigators

Principal Investigator:

Armand Christophe, MD, PhD

University Hospital, Ghent

More Information

Additional Information:

Website University Hospital Ghent This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	2001/220
Study First Received:	September 12, 2005
Last Updated:	December 19, 2007
ClinicalTrials.gov Identifier:	NCT00221546 History of Changes
Health Authority:	Belgium: Institutional Review Board

Study placed in the following topic categories:

Digestive System Diseases
Genetic Diseases, Inborn
Respiratory Tract Diseases
Cystic Fibrosis

Fibrosis
Lung Diseases
Infant, Newborn, Diseases
Pancreatic Diseases

Additional relevant MeSH terms:

Pathologic Processes
Digestive System Diseases
Genetic Diseases, Inborn
Respiratory Tract Diseases
Cystic Fibrosis

Fibrosis
Lung Diseases
Infant, Newborn, Diseases
Pancreatic Diseases

ClinicalTrials.gov processed this record on September 11, 2009